For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies stabilize the transthyretin protein, halting its destructive build-up and l